Holen Sie sich die Stockscreener-App
24.49
0.49%
-0.12
Handel nachbörslich:
24.49
Schlusskurs vom Vortag:
$24.61
Offen:
$24.51
24-Stunden-Volumen:
10.21M
Relative Volume:
1.01
Marktkapitalisierung:
$9.53B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-2.8053
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-2.97%
1M Leistung:
-0.97%
6M Leistung:
-22.20%
1J Leistung:
-61.69%
1-Tages-Spanne:
$23.91
$24.78
1-Wochen-Bereich:
$23.91
$27.10
52-Wochen-Spanne:
$23.15
$67.96
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.49 | 9.58B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna Inc. (MRNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Bank Pictet & Cie Europe AG Grows Holdings in Moderna, Inc. $MRNA - MarketBeat
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough' - Benzinga
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - Corpus Christi Caller-Times
Moderna (MRNA) Dips More Than Broader Market: What You Should Know - sharewise.com
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Bergen Record
Moderna Stands By UK As Pharma Giants Criticize PricingModerna (NASDAQ:MRNA) - Benzinga
Moderna at Bernstein Forum: mRNA Oncology Innovations - Investing.com India
Moderna at Bernstein Forum: mRNA Oncology Innovations By Investing.com - Investing.com UK
November 7th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna (MRNA) Shares Dip Amid New UK Facility Announcement - GuruFocus
New Moderna Plant Provides Relief For Under-Fire UK - insights.citeline.com
Moderna opens mRNA production center in UK - MarketScreener
Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows - AOL.com
Moderna opens UK vaccine manufacturing facility - Yahoo Finance
Moderna, Inc. $MRNA is TB Alternative Assets Ltd.'s 8th Largest Position - MarketBeat
Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility - The Guardian
Moderna opens new vaccine production facility in Oxfordshire, UK - Pharmaceutical Technology
Moderna opens new manufacturing and R&D facility in the UK - Yahoo Finance
Moderna opens UK facility as drug pricing spat rumbles on - pharmaphorum
Moderna (MRNA) Launches UK Facility for mRNA Vaccine Production - GuruFocus
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - ACCESS Newswire
Moderna opens new vaccine facility in boost for UK pharmaceutical industry - Yahoo
Moderna: Maintaining Sell Despite ConsolidationAnd Why MRNY Won't Help Either - Seeking Alpha
Brookline Capital Markets Reaffirms Their Buy Rating on Moderna (MRNA) - The Globe and Mail
Voya Investment Management LLC Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study - Stocktwits
Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers - Yahoo Finance
Green defies FDA vaccine rules - Aloha State Daily
Moderna: Updated COVID-19 vaccine generates strong immune response - McKnight's Long-Term Care News
Moderna Inc. Stock Sheds 2.9%, Underperforms Peers - 富途牛牛
Moderna’s COVID-19 vaccine shows strong response against LP.8.1 variant By Investing.com - Investing.com South Africa
Australia bets on mRNA as Moderna builds regional hub - BioWorld MedTech
Moderna stock rises as Brookline reiterates Buy on strong COVID vaccine data - Investing.com
Is Moderna Stock A Sell Following A Tough Meeting With CDC Advisors? - Investor's Business Daily
Moderna's (MRNA) New COVID-19 Vaccine Shows Promising Results in Phase 4 Trial - GuruFocus
Stocks making big moves yesterday: Plug Power, Moderna, Magnite, Compass, and RE/MAX - TradingView
Moderna announces positive prelim immunogenicity data for 2025-2026 formula of mNEXSPIKE - MarketScreener
Moderna updates late-stage trial data for redesigned COVID shot - Seeking Alpha
Moderna Says its 2025-26 COVID-19 Vaccine Appears to Generate Positive Immune Response for LP.8.1 Variant - MarketScreener
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans - Lelezard
Moderna (MRNA) Shows Promising Results with New COVID-19 Vaccine Formula - GuruFocus
Moderna’s COVID-19 vaccine shows strong response against LP.8.1 variant - Investing.com
Moderna says updated next-generation COVID shot shows strong immune response in patients - Reuters
Sumitomo Mitsui DS Asset Management Company Ltd Sells 26,032 Shares of Moderna, Inc. $MRNA - MarketBeat
Swedbank AB Sells 16,356 Shares of Moderna, Inc. $MRNA - MarketBeat
Inside Biotech: Moderna puts numbers on Australia’s mRNA investment - Proactive financial news
Why Moderna (MRNA) Stock Is Trading Up Today - Yahoo Finance
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.41%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):